Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Voigt, N; Heijman, J; Dobrev, D.
New antiarrhythmic targets in atrial fibrillation
FUTUR CARDIOL. 2015; 11(6): 645-654.
Doi: 10.2217/fca.15.67
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Heijman Jordi
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Atrial fibrillation (AF) is the most common cardiac arrhythmia in developed countries. AF is associated with increased mortality and morbidity due to thromboembolism, stroke and worsening of pre-existing heart failure [1]. Currently available pharmacological therapies for AF suffer from unsatisfying efficacy and/or are associated with major side effects such as bleeding complications or proarrhythmia [2]. These limitations largely result from the fact that most of the currently available drugs were developed on an empirical basis, without precise knowledge of the molecular mechanisms underlying the arrhythmia. During the last decade substantial progress has been made in understanding the molecular mechanisms contributing to the initiation and maintenance of AF. This knowledge is expected to stimulate the development of safer and more effective drugs. Here, we review new antiarrhythmic drug targets, which have emerged based on this increasing knowledge about the molecular mechanisms of AF.
- Find related publications in this database (Keywords)
- atrial remodeling
- delayed after depolarizations (DADs)
- re-entry
- triggered/ectopic activity